Cargando…
The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
Current pharmacological treatments of axial spondyloarthritis (axSpA) are limited to non-steroidal anti-inflammatory drugs (NSAIDs) and biological agents, including TNFα inhibitors and IL-17 inhibitors. Despite the availability of these agents, many patients either fail to respond adequately, lose t...
Autor principal: | Toussirot, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951918/ https://www.ncbi.nlm.nih.gov/pubmed/35337068 http://dx.doi.org/10.3390/ph15030270 |
Ejemplares similares
-
The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights
por: Toussirot, Eric
Publicado: (2021) -
Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis
por: Paroli, Marino, et al.
Publicado: (2023) -
The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019) -
Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials
por: Toussirot, Eric, et al.
Publicado: (2016) -
Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022)